Vaxart, Inc. announced the creation of an eight-member Scientific and Clinical Advisory Board. The Advisory Board, whose first meeting occurred on July 24, 2021, is comprised of medical and health care professionals who are vaccine, research, and academic experts in immunology, microbiology, and infectious diseases. The eight leaders joining Vaxart'sScientific and Clinical Advisory Board are: Ralph Baric, Ph.D., is a Distinguished Professor in the Department of Epidemiology and a Professor in the Department of Microbiology and Immunology. In addition, he is a World Technology Award Finalist and a fellow of the American Association for Microbiology. He has spent the past three decades as a world leader in the study of coronaviruses and is responsible for UNC-Chapel Hill's world leadership in coronavirus research. The Baric Lab uses coronaviruses as models to study the genetics of RNA virus transcription, replication, persistence, pathogenesis, genetics, and cross-species transmission. He has used alphavirus vaccine vectors to develop novel candidate vaccines. Robert Belshe, M.D., directed the NIH-funded Vaccine and Treatment Evaluation Unit (VTEU) at St. Louis University for the past three decades. His clinical and laboratory research interests include the development of live attenuated respiratory virus vaccines. Recent clinical projects include the evaluation of novel vaccines for influenza, including the live attenuated influenza vaccine available for children and adults aged 2-49. Belshe coordinated 50 other academic centers to evaluate a subunit vaccine for HSV2 in women ages 18-30. More than 8,300 women participated in the trial. Stefan Gravenstein, M.D., is a professor in the departments of Medicine and Health Services Policy and Practice at Brown University's schools of medicine and public health and serves as the Director of the Division of Geriatrics and Palliative Medicine at the Alpert Medical School of Brown University. Gregory C. Gray, M.D., MPH, FIDSA is an infectious disease epidemiologist and Professor at Duke University with three affiliations: The Division of Infectious Diseases in Duke University's School of Medicine, the Duke Global Health Institute, and the Duke Nicholas School of the Environment. He also serves as a Professor in the Program in Emerging Infectious Diseases and the Global Health Institute at Duke-NUS Medical School, Singapore, and as a Professor of Global Health at Duke Kunshan University in China. Harry B. Greenberg, M.D., the Joseph D. Grant Professor in the School of Medicine and Associate Dean for Research at Stanford University was the lead inventor of the first-generation vaccine for rotavirus, a severe diarrheal disease that kills between 300,000 and 400,000 children each year in the developing world. Marion Pepper graduated with a bachelor's degree in Biology and English from Williams College and received her Ph.D. in Immunology in 2006 from the University of Pennsylvania. She completed postdoctoral training at the University of Minnesota and joined the Department of Immunology as an Assistant Professor in 2011, and was promoted to Associate Professor 2017. Stanley A. Plotkin, M.D., is an Emeritus Professor at the University of Pennsylvania and an Adjunct Professor at Johns Hopkins University. Until 1991, he was Professor of Pediatrics and Microbiology at the University of Pennsylvania, Professor of Virology at the Wistar Institute, and at the same time, Director of Infectious Diseases and Senior Physician at the Children's Hospital of Philadelphia. In 1991, Plotkin left the University to join the vaccine manufacturer, Pasteur-Mérieux-Connaught, where for seven years he was the Medical and Scientific Director, based at Marnes-la-Coquette, now known as Sanofi Pasteur. George R. Siber, M.D., is an internationally recognized vaccine expert with 40 years of experience in developing numerous innovative vaccines. From 1975 to 1996, Dr. Siber served on the Faculty of Medicine at Harvard University as Assistant and Associate Professor of Medicine based at the Dana Farber Cancer Institute. Concurrently, from 1982 to 1996, Dr. Siber was Director of the Massachusetts Biologic Laboratories. Under his leadership, the laboratory developed specific immune globulins to CMV (Cytogam) and to RSV (Respigam) the precursor product to Synagis.